Results 21 to 30 of about 3,302 (197)

Kinetics of intestinal ultrasound and shear-wave elastography to assess early response in ulcerative colitis patients treated with filgotinib. [PDF]

J Crohns Colitis
Background and Aims A reduction of bowel wall thickness (BWT) on intestinal ultrasound (IUS) predicts endoscopic response in ulcerative colitis (UC). Advanced techniques such as shear-wave elastography (SWE) might enhance response assessment. We aimed to
Pruijt MJ, Teichert C, De Voogd FA, Janssen RJ, Löwenberg M, Goetgebuer RL, D'Haens GR, Gecse KB.   +7 more
europepmc   +2 more sources

Filgotinib in Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis of Efficacy and Adverse Events. [PDF]

Healthcare (Basel)
Background: Filgotinib is an emerging Janus kinase 1 (JAK1) inhibitor being investigated for inflammatory bowel disease. This systematic review and network meta-analysis (NMA) evaluated the efficacy and safety of filgotinib in adult patients with ...
Khoshaim YA, Habis YZ, Daqnah AG, Alqurashi RK, Abdulrahim YS, Sakkat A, Alsubhi SA, Almuwlad DT, Bukhari HS, Shogdar AJ, Amir OA, Zaazouee MS.   +11 more
europepmc   +2 more sources

Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective [PDF]

Intestinal Research
In real-world clinical practice, 3 Janus kinase (JAK) inhibitors—tofacitinib, filgotinib, and upadacitinib—are now available for the treatment of ulcerative colitis.
Shintaro Akiyama
doaj   +2 more sources

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study [PDF]

Intestinal Research
Background/Aims Real-world data on the use of filgotinib (FILGO) in patients with ulcerative colitis (UC) are limited. This study aims to provide consistent results on the effectiveness and safety of FILGO in treating UC.
Antonio Tursi, Giammarco Mocci, Francesco Costa, Linda Ceccarelli, Edoardo Savarino, Caterina De Barba, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Manuela Marzo, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Antonietta Gerarda Gravina, Raffaele Pellegrino, Rocco Spagnuolo, Francesco Luzza, Antonio Cuomo, Laura Donnarumma, Giovanni Maconi, Giovanni Cataletti, Lorenzo Bertani, Giorgia Bodini, Andrea Pasta, Simona Piergallini, Mariaelena Serio, Antonella Scarcelli, Pietro Capone, Fabio Cortellini, Stefano Rodino, Ladislava Sebkova, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Federica Gaiani, Stefano Kayali, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Antonio Ferronato, Davide Giuseppe Ribaldone, Giovanni Aragona, Patrizia Perazzo, Giacomo Forti, Michela Di Fonzo, Federico Iacopini, Roberta Pica, Claudio Cassieri, Francesca Maria Onidi, Paolo Usai Satta, Walter Elisei, Marcello Picchio, Alfredo Papa   +56 more
doaj   +2 more sources

Refractory Pyostomatitis Vegetans With Multiple Aseptic Cutaneous Abscesses Successfully Treated With Filgotinib in Ulcerative Colitis

JEADV Clinical Practice
We report on a 31‐year‐old male patient diagnosed with active moderate‐to‐severe ulcerative colitis and a history of splenectomy. He was hospitalized due to confluent pustular oral lesions and multiple skin abscesses.
C. Dandoy, D. Franchimont, C. Delvaux, A. Buggenhout, D. Bernardi, V. Del Marmol, J. M. L. White   +6 more
doaj   +2 more sources

Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort. [PDF]

Rheumatol Ther
The efficacy and safety of filgotinib (FIL) for the treatment of patients with rheumatoid arthritis (RA) have been evaluated in a number of randomized controlled trials.
Celletti E, Di Penta M, Ariani A, Parisi S, Andracco R, Raffeiner B, Ianniello A, Lo Gullo A, Molica Colella AB, Priora M, Paroli M, Lumetti F, Ravagnani V, Girelli F, Vitetta R, Volpe A, Scolieri P, Bezzi A, Ometto F, Visalli E, Farina A, Del Medico P, Bravi E, Colina M, Larosa M, Serale F, Franchina V, Molica Colella F, Ferrero G, Sandri G, Addimanda O, Reta M, Mascella F, Focherini MC, Fiorenza A, Rovera G, Giampietro C, Bernardi S, Mansueto N, Camellino D, Caccavale R, Nucera V, Sabatini E, Del Biondo P, Ditto MC, Platè I, Adorni G, Di Donato E, Santilli D, Lucchini G, Amato G, De Lucia F, Dal Bosco Y, Foti R, Smerilli G, Bianchi G, Foti R, Arrigoni E, Marchetta A, Bixio R, Bruzzese V, Fusaro E, Giuggioli D, Salvarani C, Cipollone F, Becciolini A.   +65 more
europepmc   +2 more sources

Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis

Indian Journal of Rheumatology
This review aims to provide a comprehensive analysis of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, and its potential applications in the treatment of rheumatoid arthritis (RA). It assesses filgotinib’s efficacy, safety, and role compared to
Krishna. S Upadhye, Paritosh Tayade, Hariom Patidar, Narendra Yadav   +3 more
doaj   +2 more sources

Filgotinib: First Approval [PDF]

Drugs, 2020
Filgotinib (Jyseleca®) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sciences for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and inflammatory bowel disease.
Dhillon, Sohita, Keam, Susan J.
openaire   +2 more sources

Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects

Clinical and Translational Science, 2022
Filgotinib, a preferential Janus Kinase‐1 inhibitor, is approved in Europe and Japan for treatment of rheumatoid arthritis and is being developed for treatment of other chronic inflammatory diseases. Three drug‐drug interactions studies were conducted in
Chia‐Hsiang Hsueh, Kacey Anderson, Gong Shen, Chohee Yun, Ann Qin, Ahmed A. Othman   +5 more
doaj   +1 more source

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

RMD Open, 2020
Objectives Patients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking.
Sam Lim, Matthew Baker, Vimal Derebail, Yashaar Chaichian, Mark Genovese, Panduranga Rao, Winn Chatham, Michael Bubb, Hooman Hajian, Oksana Gurtovaya, Uptal Patel, James Tumlin   +11 more
doaj   +1 more source